Opportunity Information: Apply for RFA DA 10 012
Apply for RFA DA 10 012
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "2010 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 18, 2009 and posted on Dec 18, 2009.
- Applicants must submit their applications by Jun 2, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal governments (Federally recognized) State governments Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) is a National Institutes of Health funding opportunity designed to back exceptionally creative scientists whose ideas could meaningfully change how the field approaches HIV/AIDS prevention and treatment in the context of drug abuse. The central goal is to complement NIDA's standard investigator-initiated grants by giving selected investigators the freedom and support to pursue bold, high-impact projects that could open entirely new research directions or lead to new prevention and treatment strategies for HIV/AIDS among people who use drugs. In this program, "avant garde" is used in its literal sense: proposals are expected to be genuinely unconventional and potentially transformative, not just incremental improvements on existing work.
A key expectation is that the proposed research should be substantially different from what the investigator is already doing and also distinct from mainstream approaches in the broader field. The work must also align with priority areas described in the Trans-NIH Plan for HIV-Related Research, meaning applicants need to situate their ideas within NIH-wide strategic priorities for HIV research rather than treating the award as a general innovation fund. In practice, this means the best-fit projects are likely to be those that bridge disciplines, introduce novel methodologies, or rethink accepted assumptions about HIV risk, transmission, prevention uptake, treatment delivery, or related behavioral and biological mechanisms specifically relevant to drug-abusing populations.
The competition is structured as a two-phase process. First, applicants were required to submit a pre-application under a separate solicitation (PAR-10-068). Those pre-applications were reviewed by external reviewers, and only the most outstanding submissions were invited to move forward to the second phase, which is the full application submitted under this Funding Opportunity Announcement. Final awardees for the 2010 cycle are selected only from this invited pool, so the full-application stage is not open to researchers who did not come through the pre-application screen.
This opportunity uses the NIH DP1 grant mechanism, which is typically associated with supporting high-risk, high-reward research concepts and individual investigator vision. For the 2010 fiscal year, NIDA anticipated committing about $2,000,000 total, with an expected 2 to 3 awards depending on the quality of applications received. The listed award ceiling is $500,000. There is no cost sharing or matching requirement.
Administratively, the opportunity is identified as RFA-DA-10-012, posted December 18, 2009, with an application closing date of June 2, 2010, and an archive date of July 3, 2010. It falls under CFDA 93.279 (Drug Abuse and Addiction Research Programs) and is categorized as a discretionary grant in the education and health activity area. Eligibility is broad and includes many organization types such as public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), small businesses, for-profit organizations other than small businesses, state governments, U.S. territories or possessions, and a wide range of tribal and minority-serving entities. The eligibility list also explicitly includes groups such as Historically Black Colleges and Universities, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, tribally controlled colleges and universities, faith-based or community-based organizations, regional organizations, and eligible federal agencies.
Overall, the program is best understood as a targeted, innovation-driven HIV/AIDS research award that is tightly focused on drug abuse-related HIV challenges, intentionally selective through its two-step review process, and designed to fund a small number of investigators whose ideas could shift the direction of the field rather than simply extend existing research lines.
Frequently Asked Questions (FAQ)
What is the 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1)?
It is a National Institutes of Health (NIH) funding opportunity from the National Institute on Drug Abuse (NIDA) designed to support exceptionally creative scientists pursuing bold, potentially transformative HIV/AIDS research in the context of drug abuse. The program is meant to enable high-impact projects that could change how the field approaches HIV/AIDS prevention and treatment among people who use drugs.
What is the main purpose of this award program?
The central purpose is to complement NIDA's standard investigator-initiated grants by giving selected investigators the freedom and support to pursue unconventional, high-risk/high-reward ideas. The aim is to open entirely new research directions or lead to new prevention and treatment strategies for HIV/AIDS in drug-abusing populations.
What does "avant garde" mean in this program?
"Avant garde" is used in its literal sense. Proposals are expected to be genuinely unconventional and potentially transformative, rather than incremental improvements on existing work.
How is this program different from typical NIH investigator-initiated grants?
This program is intentionally designed to fund a small number of investigators with bold, high-impact concepts and to provide latitude to pursue those concepts. It is positioned as a complement to standard grants, emphasizing unconventional approaches over extensions of established research lines.
What research focus is expected for projects under this opportunity?
Projects must focus on HIV/AIDS prevention and treatment in the context of drug abuse. The best fit is research that addresses HIV risk, transmission, prevention uptake, treatment delivery, or related behavioral and biological mechanisms specifically relevant to people who use drugs.
Does the proposed research need to be different from the investigator's current work?
Yes. A key expectation is that the proposed research should be substantially different from what the investigator is already doing.
Does the proposed approach need to be different from mainstream work in the field?
Yes. The proposed research is expected to be distinct from mainstream approaches in the broader field, with an emphasis on genuinely unconventional and potentially transformative ideas.
Does the project need to align with any NIH-wide priorities?
Yes. The work must align with priority areas described in the Trans-NIH Plan for HIV-Related Research. Applicants are expected to place their ideas within NIH-wide strategic priorities for HIV research rather than treating the award as a general innovation fund.
What kinds of projects are likely to be a strong fit?
Based on the description, strong-fit projects are likely to bridge disciplines, introduce novel methodologies, or rethink accepted assumptions about HIV risk, transmission, prevention uptake, treatment delivery, or related mechanisms, specifically as they relate to drug-abusing populations.
What is the grant mechanism used for this opportunity?
This opportunity uses the NIH DP1 grant mechanism, which is typically associated with supporting high-risk, high-reward research concepts and the vision of an individual investigator.
How does the application and review process work?
The competition is a two-phase process. First, applicants were required to submit a pre-application under a separate solicitation (PAR-10-068). Pre-applications were reviewed by external reviewers, and only the most outstanding were invited to submit a full application under this Funding Opportunity Announcement.
Can someone submit a full application without having submitted a pre-application?
No. Final awardees for the 2010 cycle are selected only from the invited pool that advanced from the pre-application stage. The full-application stage is not open to researchers who did not come through the pre-application screen.
What is the Funding Opportunity Announcement (FOA) identifier?
The opportunity is identified as RFA-DA-10-012.
When was this funding opportunity posted?
It was posted on December 18, 2009.
What was the application closing date for the full application?
The application closing date was June 2, 2010.
When was the opportunity archived?
The archive date was July 3, 2010.
How much funding did NIDA anticipate committing for fiscal year 2010?
For the 2010 fiscal year, NIDA anticipated committing approximately $2,000,000 total.
How many awards were expected to be made?
NIDA expected 2 to 3 awards, depending on the quality of applications received.
What is the listed award ceiling?
The listed award ceiling is $500,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
What is the CFDA number associated with this opportunity?
The opportunity falls under CFDA 93.279, Drug Abuse and Addiction Research Programs.
How is this grant categorized?
It is categorized as a discretionary grant in the education and health activity area.
Who is eligible to apply?
Eligibility is broad and includes many organization types, such as public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), small businesses, for-profit organizations other than small businesses, state governments, U.S. territories or possessions, and a wide range of tribal and minority-serving entities. The eligibility list also explicitly includes Historically Black Colleges and Universities, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, tribally controlled colleges and universities, faith-based or community-based organizations, regional organizations, and eligible federal agencies.
Are federal agencies eligible?
Yes. The eligibility list explicitly includes eligible federal agencies.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly included in the eligibility list.
Are small businesses eligible?
Yes. Small businesses are included in the eligibility list.
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are included in the eligibility list.
Are organizations without 501(c)(3) status eligible?
Yes. Nonprofit organizations with and without 501(c)(3) status are included in the eligibility list.
Are minority-serving institutions specifically included?
Yes. The eligibility list explicitly includes multiple minority-serving entities, including Historically Black Colleges and Universities and Hispanic-serving institutions, among others.
What is the overall takeaway about how selective this program is?
The program is intentionally selective. It uses a two-step process with a pre-application screen, and only invited applicants can submit full applications. It is designed to fund a small number of investigators whose ideas could shift the direction of the field.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Emergency Medical Services for Children State Partnership Demonstration Grants
Previous opportunity: Pre Application for the 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (X02)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 10 012
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 10 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) Apply for RFA CA 10 502 Funding Number: RFA CA 10 502 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanism for Time Sensitive Drug Abuse Research (R01) Apply for PAR 10 072 Funding Number: PAR 10 072 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 10 009 Funding Number: RFA CA 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Image Guided Cancer Interventions (SBIR R43/R44) Apply for PA 10 079 Funding Number: PA 10 079 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Image Guided Cancer Interventions (STTR R41/R42) Apply for PA 10 080 Funding Number: PA 10 080 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 10 082 Funding Number: PAR 10 082 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Systems Biology, HIV/AIDS, and Substance Abuse (R01) Apply for RFA DA 10 014 Funding Number: RFA DA 10 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Pre Application for the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02) Apply for PAR 10 095 Funding Number: PAR 10 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 10 013 Funding Number: RFA DA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for Substance Related Disorders (R01) Apply for RFA DA 10 018 Funding Number: RFA DA 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Deep Sequencing and Analysis of Pharmacogenomic Regions Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01) Apply for RFA DA 10 019 Funding Number: RFA DA 10 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 10 001 Funding Number: RFA RM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R01) Apply for PAS 10 097 Funding Number: PAS 10 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R34) Apply for PAS 10 098 Funding Number: PAS 10 098 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R01) Apply for RFA NR 10 001 Funding Number: RFA NR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21) Apply for RFA NR 10 002 Funding Number: RFA NR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 10 108 Funding Number: PA 10 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition U54) Apply for RFA CA 10 503 Funding Number: RFA CA 10 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R21) Apply for RFA NR 10 007 Funding Number: RFA NR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R01) Apply for RFA NR 10 006 Funding Number: RFA NR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 10 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.